With an expiration date still more than a year away, here's what the latest details reveal.

FDA fast tracks ADHD drug centanafadine, targeting approval by July 24 for treatment across all age groups, based on phase 3 trial results.

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

An ADHD diagnosis means a person is prone to impulsivity and distractibility, which can manifest in the form of substance misuse, traffic accidents, criminality and even suicidal behavior. A recent ...

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

Treatment linked to reduced rates of first occurrence of suicidal behaviors, substance misuse, transport accidents, criminality. HealthDay News — Attention-deficit ...

Shire’s experimental drug to treat attention-deficit hyperactive disorder showed positive results in a recent study, bringing the company one step closer to earning approval from the Food and Drug ...